Calquence® tablet (acalabrutinib), manufactured by AstraZeneca Pharmaceuticals, are a new formulation with the same indications as their previously approved capsules, including adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and for those with relapsed or refractory mantle cell lymphoma (MCL).
- Calquence capsules were originally approved in 2017.
- Recommended dosing for Calquence tablets for patients with MCL, CLL, or SLL is 100 mg, taken orally approximately every 12 hours until disease progression or unacceptable The WAC for Calquence oral capsule 100 mg is $14485.92 for a 30-day supply.
